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Safety of Intraperitoneal Injection of Adipose Tissue-Derived
Autologous Mesenchymal Stem Cells in Cats
M. Parys, N. Nelson, K. Koehl, R. Miller, J.B. Kaneene, J.M. Kruger, and V. Yuzbasiyan-Gurkan
Background: Chronic inﬂammatory diseases are common in cats and mesenchymal stem cells (MSC) are a promising ther-
apeutic approach for management of these disorders. The purpose of this study was to evaluate the safety of intraperitoneal
injection of MSC in cats.
Hypothesis: Intrapertioneal injection of autologous MSC in cats is safe.
Animals: Ten healthy adult purpose-bred cats.
Methods: Mesenchymal stem cells were isolated from subcutaneous adipose tissue collected during ovariohysterectomy
and characterized for expression of CD90, CD105 and CD44 and trilineage diﬀerentiation. Three weeks postoperatively a
complete blood count, serum chemistry proﬁle, urinalysis, and abdominal ultrasound were performed. Five cats then received
1 9 106 of autologous MSC/kg of body weight intraperitoneally with ultrasound guidance; 5 additional cats were sham
injected. Cats were monitored for 6 weeks with daily physical examinations and weekly clinicopathological evaluations.
Abdominal ultrasonography was repeated at weeks 1 and 5 after injection.
Results: Serious adverse eﬀects were not observed in any MSC-injected cat. Two animals developed transient lethargy
and decreased activity. Jejunal lymph node size was increased in MSC-injected cats compared to controls at weeks 1
(1.38  0.25 versus 0.88  0.25 cm2; P = .036) and 5 (1.75  0.82 versus 0.79  0.12 cm2; P = .047). A hyperechoic renal
segmental cortical lesion was observed in 1 MSC-injected cat.
Conclusions and Clinical Relevance: Intraperitoneal MSC injection was well tolerated with only mild, self-limiting adverse
eﬀects being observed in 2 cats. This route provides a safe means of administration for cell-based treatment in cats.
Key words: Feline; Inﬂammatory disease; Regenerative medicine; Route of injection.
Administration of mesenchymal stem cells (MSC)has been recently proposed as an alternative thera-
peutic modality for management of chronic inﬂamma-
tory conditions in cats and other species.1–3 MSC
express a myriad of factors such as IDO, IL10, HGF,
PGE2, TGF-beta, IL6, PD-L1, FASL or HMOX14–15
and aﬀect the immunomodulating properties of many
types of immune cells.12,16–20 Interestingly, MSC are
capable of inducing T-regulatory cells, which in turn
can provide a long-lasting immunomodulation.21 In
vitro experiments suggest that MSC need to be in close
proximity to target cells and in suﬃcient quantity to
induce a therapeutic eﬀect.11,13,14,18,22 In addition,
in vivo experiments also suggest paracrine eﬀects of
MSCs on other cells are also important.15,23,24
Multiple routes of injection of MSC are described
and include intravenous (IV), intraperitoneal (IP) as
well as intra-articular, cardiac, hepatic or nasal.1,24–27
IV injection is a frequently reported route of MSC
administration for immunomodulation.1,2,15,22,24–29
However, IV administration of MSC has potential limi-
tations for treatment of inﬂammatory conditions local-
ized to the peritoneal cavity. Exposure of IV
administered MSC to plasma complement reduces cell
survival.30 Retention of MSC in pulmonary vasculature
reduces the number of cells reaching the target and
increases the risk of pulmonary microthrombus forma-
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PGE2 prostaglandin E2
TGF-beta transforming growth factor beta
IL6 interleukin-6
PD-L1 programmed death ligand 1
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tion.31,32 Pulmonary thrombosis is a potential serious
complication and might increase morbidity and mortal-
ity.2 Furthermore, instant blood mediated inﬂammatory
reaction (IBMIR) occurs after injection of MSC and
can be cause of decreased cell survival and increased
risk of thromboembolism.33–36 Thus, IV injection can
potentially limit the availability of MSC and their
migration capabilities, decrease the overall cell survival,
and increase risk of adverse eﬀects.30
Intraperitoneal injection is potentially a safer and
more eﬀective route of MSC administration for disor-
ders within the abdominal cavity. IP-injected MSC are
placed in close proximity to the target organ and could
reach the target in greater numbers and subsequently
eﬀect a better outcome. IP injection is simple to per-
form and has the promise of widespread adoption in
clinical settings and high impact on patient manage-
ment. IP injection of MSC was signiﬁcantly more eﬀec-
tive than IV administration for ameliorating clinical
signs in a rodent model of inﬂammatory bowel dis-
ease.37 MSC, administered IP have been studied also
for their regenerative potential38 and ability to deliver
gene treatment.39,40
The safety of IP injection of MSC has not been stud-
ied in the cats. This study was undertaken to test the
hypothesis that IP injection is a safe route of autolo-
gous MSC administration in cats.
Materials and Methods
Animals
Ten purpose-bred mixed breed, intact female cats were obtained
from the MSU Comparative Ophthalmology Cat Colony and from
a licensed commercial vendor,a 5 from each source. The mean age
(SD) at the time of injection of the cats was 20.7 (5.7) months
and the mean (SD) weight was 3.79 (0.5) kg. Animals were
housed under standard conditions at the Michigan State Univer-
sity College of Veterinary Medicine Vivarium, fed a commercial
dietb and received environmental enrichment during the study per-
iod. Cats were determined to be healthy on the basis of physical
examination. The study was approved by the Michigan State
University Institutional Care and Animal Use Committee.
Isolation and Characterization of MSC
Subcutaneous adipose tissue (2–4 g) from the ventral midline
abdomen was collected during ovariohysterectomy was placed in
KNAC medium (Keratinocyte SFM mediumc supplemented with
2 mM of N-acetyl-L-cysteined and 0.2 mM of L-ascorbic acid
2-phosphated) with 5% of MSC-grade FBSe in 50 mL tube for
transfer to the laboratory for processing. Each tissue sample was
ﬁnely minced with sterile scalpel blade and incubated in 1 mg/mL
of Collagenase Id in HBSSd for 2 hours at 37°C with 5% CO2.
After incubation, the cell suspension was repeatedly aspirated with
sterile serological pipette to facilitate dissociation and passed
through a 70 lm cell strainerf to remove excess tissue stroma. The
resulting cell suspension was washed twice in sterile PBS by cen-
trifugation at 467 9 g for 5 minutes at room temperature. Cells
were then resuspended in 5 mL of KNAC medium with 5% of
MSC-grade FBSe and plated in T-25 plastic tissue culture ﬂask.g
After reaching 80% conﬂuency, cells were trypsinized with 0.05%
trypsin,h resuspended in 20 mL of medium and divided between 2
T-75 plastic tissue culture ﬂasks.g All cell cultures were
subsequently passaged in a similar fashion until suﬃcient quanti-
ties of cells were available for injection and characterization, which
took approximately 3 weeks.
Adherent cells were characterized for cell surface expression of
CD90,i CD105,j CD44,k MHCIIl and for diﬀerentiation into osteo-
cytes, adipocytes, and chondrocytes.1,41,42 Cell membrane marker
expression was analyzed by ﬂow cytometrym and analyzed using
commercial software.n Diﬀerentiation of cells was achieved
through use of commercial osteogenesis, adipogenesis, and chon-
drogenesis kits,o,p according to manufacturer’s recommendations.
For osteogenesis and adipogenesis experiments, 1 9 104 and
1 9 105 cells per well were plated in 24-well tissue culture plates
containing KNAC medium with 5% FBS and incubated at 37°C
for 24 hours to allow cells to attach. After incubation, the medium
was changed to the speciﬁc diﬀerentiation medium and cultured
for 3 weeks in 37°C with 5% CO2 with medium being changed
twice a week. Chondrogenic diﬀerentiation was accomplished
through culture of at least 1 9 106 cells in micromass. Cells were
re-suspended in 1 mL of cell culture medium and spun down at
325 9 g for 5 minutes. Subsequently, the medium was carefully
exchanged with chondrogenesis medium, in order not to disrupt
the pellet. Cells were then cultured for 3 weeks at 37°C with 5%
CO2, with semiweekly medium changes. After 3 weeks of diﬀeren-
tiation, the cells were stained with Alizarin Redd to assess osteo-
genic diﬀerentiation, Alcian Blued to assess chondrogenesis and
Oil-o-Redd stain to assess adipogenesis.
Procedures
All cats underwent a routine ovariohysterectomy, at which time
a 2–4 g sample of ventral midline subcutaneous fat was obtained
and processed for MSC isolation and propagation. For ovariohys-
terectomy, animals were sedated with acepromazineq (0.05 mg/kg)
and buprenorphniner (10 mcg/kg), anesthetized with isoﬂuranes
(0.25–3% isoﬂurane in 100% oxygen in an induction chamber). For
subsequent examinations (ultrasound, blood draw, cystocentesis),
all cats were sedated or anesthetized for all procedures with either
acepromazineq (0.05 mg/kg) and buprenorphniner (10 mcg/kg) or
isoﬂuranes (0.25–3% isoﬂurane in 100% oxygen in an induction
chamber). Five cats (3 MSC-treated and 2 sham-injected) were
sedated using acepromazine and buprenorphine and 5 cats (2 MSC-
treated and 3 sham-injected) were anesthetized with isoﬂuorane.
After a 3-week recovery period from ovariohysterectomy, all
cats were evaluated at baseline (pretreatment) with a complete
physical examination, a CBC, serum chemistry proﬁle, urinalysis,
and abdominal ultrasonography. Cats were then randomly divided
into 2 groups of 5 animals each. Cats from both sources were rep-
resented in each of the groups. Group 1 cats received an ultra-
sound-guided injection of 1 9 106 autologous MSC/kg of body
weight; Group 2 control cats received an equivalent IP sham injec-
tion of sterile phosphate buﬀered saline (PBS).t MSCs were sus-
pended in 4 mL of saline for IP injections. Isolated MSCs in
passage 4 were grown to about 80–90% conﬂuence, detached using
0.05% trypsin for 10 minutes, washed twice using PBSt and quan-
tiﬁed using an electronic cell counteru and resuspended in 4 mL of
PBS for injection. The suspension was then transferred into a
20 cc syringen with a 22F needlen for injection. After injection of
MSC, cats were monitored for 6 weeks with daily physical exami-
nations and weekly clinicopathological evaluations (CBC, serum
chemistry proﬁles, and urinalyses).v Abdominal ultrasonography
was repeated at 1 and 5 weeks after injectionw with the ultrasound
examiner being blinded to each cat’s treatment status.
For ultrasonographic examinations, cats were placed in dorsal
recumbency and the abdomen was imaged using a linear array
multifrequency transducer.x The frequency used varied between 10
and 13 MHz, with the highest frequency chosen, which allowed
complete organ evaluation. During each ultrasound evaluation,
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the entire abdominal contents were surveyed, including the liver,
spleen, kidneys, bladder, adrenal glands, pancreas, stomach and
small intestines. The medial iliac and jejunal lymph nodes were
also imaged at these time periods, and their long axis (cranial to
caudal length) and short axis (dorsal to ventral height) were mea-
sured. For statistical comparisons, lymph node size was calculated
as the multiplication of length times width. At 5 weeks after injec-
tion, ﬁne needle aspirate biopsies of selected abdominal lymph
nodes were obtained from 3 MSC-treated cats under ultrasound
guidance using a 22 g 1.5 inch needle.
Statistical Analyses
Mean values with standard deviation were calculated for
MSC-treated and control cats at each sampling time for data
from physical examination, clinicopathological evaluations, and
ultrasound measurements. Comparison between the before and
after treatment results within each group were performed using
paired t-test. Continuous quantitative variables that failed
normality testing were evaluated with nonparametric analyses.
Nonparametric Wilcoxon signed-rank tests were used for
analyses of outcome variables for signiﬁcant diﬀerences between
treatment groups. In addition, multivariable ANOVA (MAN-
OVA) was used to evaluate the linear changes over time. All
data were analyzed with a commercially accessible statistical
software package.y Results with P < .05 were considered statisti-
cally signiﬁcant.
Results
Each cell preparation displayed the expected MSC-
phenotype. Cells underwent diﬀerentiation into adipo-
cytes, chondrocytes, and osteocytes (Fig 1) and strongly
expressed the surface markers CD44, CD90, CD105,
while lacking expression of MHCII (Fig 2).
Severe adverse eﬀects were not observed in any cat
after injection of MSC. There were no signiﬁcant diﬀer-
ences in mean temperature, respiratory rate, heart rate,
and body weight between groups over the course of the
study. Two MSC-treated cats were lethargic and were




Fig 1. Representative photomicrographs illustrating diﬀerentiation characterization of a mesenchymal stem cells cell line isolated from adi-
pose tissue obtained from a 2 year old, female mixed breed cat (magniﬁcation 409). (A) Lipid droplets in diﬀerentiated cells are stained red with
Oil-o-red demonstrating adipogenesis, (B) Red-colored calcium deposits inside cells stained with Alizarin red stain demonstrating osteogenesis,
(C) Blue-colored in glycosaminoglycan deposits in cells stained with Alcian Blue stain after chondrogenic diﬀerentiation. (D–F) Control pho-
tomicrographs after incubation of the same cell line in KNAC medium and stained with Oil-o-red (D), Alizarin red (E) and Alcian Blue (F).
Note lack of uptake of the stains in both micrographs (D,E) and no blue staining extracellular matrix in the chondrogenic control stain (F).
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injection. No pain was elicited by abdominal palpation
in either cat. Both cats spontaneously recovered within
1 to 3 days after injection of cells.
Results of clinicopathologic evaluations revealed sig-
niﬁcant diﬀerences between study group for creatine
kinase (CK) enzyme activity. CK activity was signiﬁ-
cantly higher in MSC-injected cats on weeks 1
(271.4  154.36 IU/L versus 150.6  54.79; P = .047,
Wilcoxon) and 3 (196  49.75 versus 125.8  34.72;
normal reference range = 59–354 IU/L; P = .047, Wil-
coxon). Individual cat CK values were above the refer-
ence range at various times in 3 MSC-injected cats and
2 sham-injected cats. Abdominal ultrasonography
revealed a signiﬁcant increase in jejunal lymph node size
in MSC-injected cats compared to controls at weeks 1
(1.38  0.25 versus 0.88  0.25 cm2; P = .036)
P = .036, Wilcoxon) and 5 (1.75  0.82 versus
0.79  0.12 cm2; P = .047, Wilcoxon) after cell injec-
tion (Fig 3). A signiﬁcant increase in lymph node size
over time was also identiﬁed in MSC-injected cats when
comparing the before injection lymph node size with
size at week 5 (1.1  0.52 cm2 before injection versus
1.75  0.82 cm2 after injection; P = .033). A hypere-
choic renal segmental cortical lesion consistent with a
renal infarct was identiﬁed sonographically in 1
MSC-injected cat 1 week after injection. Cytologic
A B
C D
Fig 2. Flow cytometric analysis of surface markers expressed by a representative cell line from the same Animal 1 as in Fig 1. Gray lines
represent the negative controls, while in black is the population of cells stained with antibody speciﬁc for each epitope. The X-axis repre-
sents the ﬂuorescence intensity of the ﬂuorophore (APC, PE or FITC) while the Y-axis represents the cell counts. Note strong expression
of all markers (A) CD90, (B) CD105, (C) CD44 in each cell line (continuous line), compared to negative control (dashed line) and lack of
expression of MHCII (D).
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examination of lymph node aspirates obtained from 3
MSC-injected animals revealed normal cell populations
consisting primarily of small lymphocytes with low
numbers of medium to large lymphocytes and occa-
sional plasma cells and macrophages; there was no
cytologic evidence of disease.
Discussion
This study evaluated the safety of IP injection of
autologous MSC in cats. Our ﬁndings show that IP
administration of autologous MSCs appears to be a
safe and technically feasible approach to cell-based
treatment in cats. Limited adverse eﬀects were observed,
manifesting as transient lethargy and decreased activity
in 2 cats. The cause of these behaviors in uncertain, but
might be related to discomfort associated with a host
response to MSC or other components of the cell
preparation. Although abdominal pain was not elicited
during palpation, increased abdominal lymph node size
in MSC-injected cats is consistent with a heightened
host response to MSC injection. Alternatively, this reac-
tion might have been caused by the sedative or anesthe-
sia used. However, the fact that this behavior was
observed only after cell injection and not at other times
the cats underwent anesthesia, suggests that an adverse
anesthetic reaction is less likely the cause of lethargy.
All clinicopathological results were similar between
MSC-injected and sham-injected animals with the
exemption of CK. Importantly, CK values were only
mildly outside of the reference ranges. Activity of this
activity can be induced by multiple factors. Cats in this
study received intramuscular injections of sedatives,
which can increase the CK values.43 Some animals
required additional physical restraint, which could result
in increase in CK as well.43
A hyperechoic renal segmental cortical lesion was
observed in 1 MSC-injected cat 1 week after injection,
which was assumed to be a renal infarct. These changes
are incidentally encountered in cats in the clinical prac-
tice setting and have been observed more frequently in
Ragdoll cats and cats with cardiomyopathy.44,45 In the
MSC-injected cat with the renal segmental cortical
lesion in this study, no heart murmur was identiﬁed on
cardiac auscultation. An echocardiogram was per-
formed to investigate for cardiomyopathy at a recheck
appointment 1 year after completion of this study and
no abnormalities were noted within the heart by a
board certiﬁed cardiologist. Interestingly, the animal
developed other similar infarcts in the other kidney at
the 1 year follow-up, which suggests that this animal is
prone to this kind of changes and suggest that the
infarcts were not related to the injected MSCs.
We also observed a signiﬁcant increase in the size of
jejunal lymph nodes in MSC-injected cats over the
course of the study. We speculate that secretion of IL6
by MSC,14 which is known to cause T-cell expansion,
may be responsible for the diﬀerences in lymph node
size observed between the 2 groups. Cytological exami-
nation of lymph nodes of a limited number of MSC-
injected animals did not reveal any pathological process.
However, proof of that hypothesis would require
histopathological evaluation of the jejunal lymph nodes.
Necropsy examinations were not part of the experimen-
tal design, so it could not be assessed. Another explana-
tion might be a complement-mediated reaction to
injected MSCs, similar to IBMIR reaction to injected
cells and subsequent activation of innate immune
system. Elements of complement are constitutively
expressed by mesothelial cells.46 C3 complement compo-
nent expressed by peritoneal mesothelial cells has been
previously implicated to be responsible for IBMIR reac-
tion after MSC IV injection in vivo and subsequent
activation of innate immune system.47 Interestingly, the
complement binding also enhances the immunomodula-
tory properties of MSCs.47 Regardless, follow-up
ultrasonograms performed on 2 MSC-injected cats
approximately 12 months after injection, revealed that
all abdominal lymph nodes had returned to pre-injec-
tion size (data not shown). These observations suggest
that abdominal lymphadenopathy associated with MSC
injection is be transient in nature. Further studies are
needed to determine the precise cause of the increased
lymph node size observed in MSC-injected cats.
A limitation of this study is that only a single dose of
MSC was evaluated. Responses to IP MSC injection
may vary by dose and frequency of administration, as
suggested by in vitro studies in other species.12,14,18,48–50
Future studies evaluating a higher dose of MSC than
the one evaluated in this study may be necessary to
fully evaluate the safety proﬁle of the IP injection in
cats.
Although the eﬃcacy of IP MSC injection has been
previously studied in a variety of species and disease
models,37–40,51 there have been few studies reported that
comprehensively investigate the safety of IP administra-
tion of MSC in healthy control animals. In one study
Fig 3. Changes in mean (SD) jejunal lymph node size in cats
injected intraperitoneally with either 1 9 106 mesenchymal stem
cells (MSC) (n = 5) or a sham preparation (n = 5) over the course
of study. *Statistically signiﬁcant diﬀerence between treatment
groups (MSC treated versus sham treated animals) at the weeks
indicated (P < .5). **Statistically signiﬁcant diﬀerence between
pre-injection and 5 week after inject lymph node size (as presented
by the black line over the graph) within the group treated with
MSCs (P = .033).
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evaluating the safety and distribution of amniotic ﬂuid
stem cells injected IP in neonatal rats,52 no adverse
eﬀects were noted in MSC-injected rats during the
21-day after injection observation period. However,
neither lymph node size nor behavioral changes were
investigated in the rat study.
We conclude that IP injection of autologous MSC in
cats is overall safe and is associated only with mild,
self-limiting, and short-lasting adverse eﬀects and pro-
vides a safe alternative route of administration for cell-
based treatment in cats. Given the apparent safety of IP
administration of MSC and the potential of IP adminis-
tered MSC to reach intra-abdominal target sites, the
eﬀectiveness of the IP route for MSC-based treatment
of chronic inﬂammatory disorders of the peritoneal cav-
ity such as chronic idiopathic cystitis, hepatitis, pancre-
atitis, or inﬂammatory bowel disease warrant further
investigations.
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